TherapeuticsMD, Inc. (TXMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350K 700K 1.1M Q3 '24: 547K Q4 '24: 667K Q1 '25: 393K Q2 '25: 952K Q3 '25: 784K Q4 '25: 893K Q1 '26: 724K Q2 '26: 869K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

-25M 0 25M 50M 75M Q1 '22: 14.5M Q2 '22: 0 Q3 '22: 0 Q4 '22: 68.6M Q1 '23: 416K Q2 '23: 437K Q3 '23: -53K Q4 '23: 502K Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Income Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q3 '24: -1.1M Q4 '24: -652K Q1 '25: -1.3M Q2 '25: -695K Q3 '25: -862K Q4 '25: -1.6M Q1 '26: -723K Q2 '26: -816K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-750K -500K -250K 0 250K 500K 750K Q3 '24: -609K Q4 '24: 252K Q1 '25: -653K Q2 '25: 551K Q3 '25: 152K Q4 '25: -619K Q1 '26: 95K Q2 '26: 155K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 2M 4M 6M Q4 '20: 5.6M Q1 '21: 4.7M Q2 '21: 4.1M Q3 '21: 5.3M Q1 '22: 695K Q2 '22: 348K Q3 '22: 354K Q4 '22: 0 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22

Operating Cash Flow Quarterly

-350K 0 350K 700K 1.1M Q3 '24: -71K Q4 '24: 17K Q1 '25: 699K Q2 '25: 381K Q3 '25: 999K Q4 '25: 375K Q1 '26: 944K Q2 '26: 779K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q4 '20: -30.5M Q1 '21: -38.4M Q2 '21: -26.6M Q3 '21: -38.3M Q4 '21: -39.6M Q1 '22: -17.9M Q2 '22: -27.1M Q3 '22: -18.9M Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 4M 8M 12M Q1 '24: 11.5M Q2 '24: 11.5M Q3 '24: 11.5M Q1 '25: 11.6K Q2 '25: 11.6M Q3 '25: 11.6M Q1 '26: 11.6K Q2 '26: 11.6M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 0.00 6.00 12.00 18.00 Q1 '23: 17.43 Q2 '23: 4.36 Q3 '23: 7.17 Q4 '23: -1.00 Q1 '24: -0.69 Q2 '24: -0.54 Q3 '24: -0.27 Q4 '24: -0.19 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.